Bismut Samuel, Schneider Matthias M, Miyasaki Masashi, Feng Yuqing, Wilde Ellis J, Gunawardena M Dylan, Knowles Tuomas P J, Kaminski Schierle Gabrielle S, Itzhaki Laura S, Kumita Janet R
Department of Pharmacology, University of Cambridge, Cambridge, UK.
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
Protein Sci. 2025 Jun;34(6):e70150. doi: 10.1002/pro.70150.
Amyloid fibrils are ordered aggregates that are a pathological hallmark of many neurodegenerative disorders including Alzheimer's disease and Parkinson's disease. The process of amyloid formation involves a complex cascade by which soluble monomeric protein converts to insoluble, ordered aggregates (amyloid fibrils). Although inhibiting the aggregation pathway is a key target for therapeutic development, the heterogeneous collection of aggregation-prone species formed in this process, including oligomers, protofibrils, and fibrils, represents other targets for modifying disease pathology. Developing molecules that can bind to amyloid fibrils and potentially disrupt the harmful interactions between the fibrils and the cellular components would be advantageous. Designing peptide modulators for α-synuclein aggregation is of great interest; however, effective inhibitory peptides are often hydrophobic and hence difficult to handle. Therefore, developing strategies to display these peptides in a soluble scaffold would be very beneficial. Here we demonstrate that the ultra-stable consensus-designed tetratricopeptide repeat (CTPR) protein scaffold can be grafted with "KLVFF" derived peptides previously identified to inhibit protein aggregation and interact with amyloid fibrils to produce proteins that bind along the surface of α-synuclein fibrils with micromolar affinity. Given the ability to insert hydrophobic peptides to produce soluble, CTPR-based binders, this method may prove beneficial in screening for peptide modulators of protein aggregation.
淀粉样纤维是有序聚集体,是包括阿尔茨海默病和帕金森病在内的许多神经退行性疾病的病理标志。淀粉样蛋白形成过程涉及一个复杂的级联反应,可溶性单体蛋白通过该反应转化为不溶性的有序聚集体(淀粉样纤维)。尽管抑制聚集途径是治疗药物开发的关键靶点,但在此过程中形成的易于聚集的物种的异质集合,包括寡聚体、原纤维和纤维,代表了改变疾病病理的其他靶点。开发能够结合淀粉样纤维并可能破坏纤维与细胞成分之间有害相互作用的分子将是有利的。设计用于α-突触核蛋白聚集的肽调节剂备受关注;然而,有效的抑制性肽通常具有疏水性,因此难以处理。因此,开发在可溶性支架中展示这些肽的策略将非常有益。在这里,我们证明了超稳定的经共识设计的四肽重复序列(CTPR)蛋白支架可以与先前鉴定出的抑制蛋白聚集并与淀粉样纤维相互作用的“KLVFF”衍生肽嫁接,以产生以微摩尔亲和力沿α-突触核蛋白纤维表面结合的蛋白质。鉴于能够插入疏水性肽以产生可溶性的基于CTPR的结合剂,该方法可能在筛选蛋白质聚集的肽调节剂方面被证明是有益的。